Genentech, Alector partner on $1.2b Parkinson’s drug deal
Alector has granted Genentech exclusive worldwide rights to develop and commercialize AL050, an investigational brain-penetrant engineered glucocerebrosidase enzyme replacement therapy enabled by Alector Brain Carrier. The program is designed to address GCase deficiency implicated in Parkinson’s dis
<p>Alector has granted Genentech exclusive worldwide rights to develop and commercialize AL050, an investigational brain-penetrant engineered glucocerebrosidase enzyme replacement therapy enabled by Alector Brain Carrier. The program is designed to address GCase deficiency implicated in Parkinson’s dis</p>